RxDoctor Payments Data

Sam Baroudi, MD

Internal Medicine · Vista, CANPI 1316936933

Payments from drug & device makers

$3,624in general payments, 2019–2025

Across 197 payments — averaging $18.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$702
  • Novartis$435
  • Amgen$379
  • Novo Nordisk$279
  • AstraZeneca$265
  • GSK$239
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$3,55298%
  • Education$722%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,624 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$310,416
Medicare patients
646
Services billed
4,772

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin162$183,754
EliquisApixaban186$145,096
Trelegy ElliptaFluticasone/Umeclidin/Vilanter142$94,536
OzempicSemaglutide81$89,783
XareltoRivaroxaban51$47,732
Repatha SureclickEvolocumab50$44,386
MyrbetriqMirabegron37$29,434
JanuviaSitagliptin Phosphate25$26,994
MounjaroTirzepatide17$22,802
TrulicityDulaglutide19$21,949
UbrelvyUbrogepant16$16,305
NexletolBempedoic Acid14$16,097
FarxigaDapagliflozin Propanediol13$10,315
Praluent PenAlirocumab11$7,102
Repatha SyringeEvolocumab11$6,736

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$21$183,754162 claims
PfizerEliquis$186$145,096186 claims
GSKTrelegy Ellipta$239$94,536142 claims
Novo NordiskOzempic$279$89,78381 claims
Johnson & JohnsonXarelto$80$47,73251 claims
Lilly USA, LLCMounjaro, Trulicity$101$44,75236 claims
Astellas Pharma US IncMyrbetriq$98$29,43437 claims
MerckJanuvia$21$26,99425 claims
AbbVieUbrelvy$702$16,30516 claims
AstraZenecaFarxiga, Brilinta$265$15,42926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Vista

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →